OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
Ahmet Uluer, Gordon MacGregor, Pilar Azevedo, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 6, pp. 550-562
Open Access | Times Cited: 45
Ahmet Uluer, Gordon MacGregor, Pilar Azevedo, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 6, pp. 550-562
Open Access | Times Cited: 45
Showing 1-25 of 45 citing articles:
The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches
Simon Y. Graeber, Marcus Mall
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1185-1198
Closed Access | Times Cited: 68
Simon Y. Graeber, Marcus Mall
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1185-1198
Closed Access | Times Cited: 68
CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis
Jennifer L. Taylor‐Cousar, Paul D. Robinson, Michal Shteinberg, et al.
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1171-1184
Closed Access | Times Cited: 64
Jennifer L. Taylor‐Cousar, Paul D. Robinson, Michal Shteinberg, et al.
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1171-1184
Closed Access | Times Cited: 64
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
Mafalda Bacalhau, Mariana Camargo, Grace Anne Vieira Magalhães Ghiotto, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 410-410
Open Access | Times Cited: 61
Mafalda Bacalhau, Mariana Camargo, Grace Anne Vieira Magalhães Ghiotto, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 410-410
Open Access | Times Cited: 61
Cystic fibrosis
Marcus Mall, Pierre–Régis Burgel, Carlo Castellani, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 27
Marcus Mall, Pierre–Régis Burgel, Carlo Castellani, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 27
Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians
Vito Terlizzi, Philip M. Farrell
Current problems in pediatric and adolescent health care (2024) Vol. 54, Iss. 6, pp. 101637-101637
Closed Access | Times Cited: 24
Vito Terlizzi, Philip M. Farrell
Current problems in pediatric and adolescent health care (2024) Vol. 54, Iss. 6, pp. 101637-101637
Closed Access | Times Cited: 24
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
Claire Keating, Lael M. Yonker, F. Vermeulen, et al.
The Lancet Respiratory Medicine (2025)
Open Access | Times Cited: 10
Claire Keating, Lael M. Yonker, F. Vermeulen, et al.
The Lancet Respiratory Medicine (2025)
Open Access | Times Cited: 10
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
Jordana E. Hoppe, Ajay S. Kasi, Jessica E. Pittman, et al.
The Lancet Respiratory Medicine (2025)
Open Access | Times Cited: 10
Jordana E. Hoppe, Ajay S. Kasi, Jessica E. Pittman, et al.
The Lancet Respiratory Medicine (2025)
Open Access | Times Cited: 10
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment
Edith T. Zemanick, Bonnie W. Ramsey, Dorota Sands, et al.
Journal of Cystic Fibrosis (2025)
Open Access | Times Cited: 4
Edith T. Zemanick, Bonnie W. Ramsey, Dorota Sands, et al.
Journal of Cystic Fibrosis (2025)
Open Access | Times Cited: 4
Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
Stavros Topouzis, Andreas Papapetropoulos, S P H Alexander, et al.
British Journal of Pharmacology (2025)
Open Access | Times Cited: 2
Stavros Topouzis, Andreas Papapetropoulos, S P H Alexander, et al.
British Journal of Pharmacology (2025)
Open Access | Times Cited: 2
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor
Vito Terlizzi, Miquéias Lopes‐Pacheco
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access | Times Cited: 2
Vito Terlizzi, Miquéias Lopes‐Pacheco
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access | Times Cited: 2
Rescue of Mutant CFTR Channel Activity by Investigational Co-Potentiator Therapy
Mafalda Bacalhau, Filipa C. Ferreira, Marcelo Folhadella M. F. Azevedo, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 82-82
Open Access | Times Cited: 1
Mafalda Bacalhau, Filipa C. Ferreira, Marcelo Folhadella M. F. Azevedo, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 82-82
Open Access | Times Cited: 1
Application of deuterium in research and development of drugs
Jiong Chen, Yuan‐Yuan Zhu, Lu Huang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117371-117371
Closed Access | Times Cited: 1
Jiong Chen, Yuan‐Yuan Zhu, Lu Huang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117371-117371
Closed Access | Times Cited: 1
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
Burkhard Tümmler
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 16
Burkhard Tümmler
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 16
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)
Matthew Heneghan, Kevin W Southern, J. Patrick Murphy, et al.
Cochrane library (2023) Vol. 2023, Iss. 11
Open Access | Times Cited: 16
Matthew Heneghan, Kevin W Southern, J. Patrick Murphy, et al.
Cochrane library (2023) Vol. 2023, Iss. 11
Open Access | Times Cited: 16
Unmet challenges in cystic fibrosis treatment with modulators
Federica Corrao, Mairead Kelly, Isabelle Sermet‐Gaudelus, et al.
Expert Review of Respiratory Medicine (2024) Vol. 18, Iss. 3-4, pp. 145-157
Closed Access | Times Cited: 5
Federica Corrao, Mairead Kelly, Isabelle Sermet‐Gaudelus, et al.
Expert Review of Respiratory Medicine (2024) Vol. 18, Iss. 3-4, pp. 145-157
Closed Access | Times Cited: 5
The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?
Kathryn E. Oliver, Marianne S. Carlon, Nicoletta Pedemonte, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 14, pp. 1545-1565
Open Access | Times Cited: 13
Kathryn E. Oliver, Marianne S. Carlon, Nicoletta Pedemonte, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 14, pp. 1545-1565
Open Access | Times Cited: 13
Ocular development after highly effective modulator treatment early in life
Yimin Zhu, Danni Li, Felisa Reyes‐Ortega, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 12
Yimin Zhu, Danni Li, Felisa Reyes‐Ortega, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 12
Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis
Xueqing Wang, Chris Tse, Ashvani K. Singh
Journal of Medicinal Chemistry (2025)
Closed Access
Xueqing Wang, Chris Tse, Ashvani K. Singh
Journal of Medicinal Chemistry (2025)
Closed Access
Tools used to measure quality of life in adults with cystic fibrosis– a systematic review
Dorota Snop-Perkowska, Jakub Świtalski, Katarzyna Wnuk, et al.
Health and Quality of Life Outcomes (2025) Vol. 23, Iss. 1
Open Access
Dorota Snop-Perkowska, Jakub Świtalski, Katarzyna Wnuk, et al.
Health and Quality of Life Outcomes (2025) Vol. 23, Iss. 1
Open Access
Innate Immunity in Cystic Fibrosis: Varied Effects of CFTR Modulator Therapy on Cell-to-Cell Communication
J. Hynes, Clifford C. Taggart, Rabindra Tirouvanziam, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2636-2636
Open Access
J. Hynes, Clifford C. Taggart, Rabindra Tirouvanziam, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2636-2636
Open Access
Comparative Efficacy of CFTR Modulators: A Network Meta-analysis
Imran H. Iftikhar, Santosh T.R.B. Rao, Rufai Nadama, et al.
Lung (2025) Vol. 203, Iss. 1
Closed Access
Imran H. Iftikhar, Santosh T.R.B. Rao, Rufai Nadama, et al.
Lung (2025) Vol. 203, Iss. 1
Closed Access
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024
Zinnet Şevval Aksoyalp, Gizem Kaykı-Mutlu, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
Zinnet Şevval Aksoyalp, Gizem Kaykı-Mutlu, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
Novel Co‐Occurrence of Trisomy 21 and Heterozygous CFTR Mutation
Majd Oweidat, Tamer Qutaina, Alzahra Akram Hamdan, et al.
Respirology Case Reports (2025) Vol. 13, Iss. 4
Open Access
Majd Oweidat, Tamer Qutaina, Alzahra Akram Hamdan, et al.
Respirology Case Reports (2025) Vol. 13, Iss. 4
Open Access
Physical well-being and burden of care in adults on modulator therapy: A mixed methods study of patient-reported experiences from the Well-ME survey
Cynthia D. Brown, Carla Frederick, Elizabeth L. Yu, et al.
Journal of Cystic Fibrosis (2025)
Closed Access
Cynthia D. Brown, Carla Frederick, Elizabeth L. Yu, et al.
Journal of Cystic Fibrosis (2025)
Closed Access
Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators
Burkhard Tümmler, Sophia T. Pallenberg, Anna‐Maria Dittrich, et al.
Molecular and Cellular Pediatrics (2025) Vol. 12, Iss. 1
Open Access
Burkhard Tümmler, Sophia T. Pallenberg, Anna‐Maria Dittrich, et al.
Molecular and Cellular Pediatrics (2025) Vol. 12, Iss. 1
Open Access
